HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and a subsidiary of HLB, today announced that the first participant has been dosed in the Phase 1 clinical trial of ITI-9001, its investigational vaccine designed to treat Japanese cedar pollen allergy.
